Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care
Published . Updated .
Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care Cure Today
Directly affected
- No company is named in this report.
Indirectly affected
- NAMS NEW AMSTERDAM PHARMA CO ORDINARY SHARES
GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- CRDF CARDIFF ONCOLOGY INC COM
GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care Cure Today
Source: Cure Today
NewAmsterdam Pharma Co N.V (NAMS) since this story, compared with the market
Since the first closing price after “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care,” NewAmsterdam Pharma Co N.V (NAMS) is +2.37%. The S&P 500 fund (SPY) is -0.40% over the same days, a +2.77% difference versus the market.
| Company | When | Move | Status |
|---|---|---|---|
| Acadia Healthcare (ACHC) | that day | +0.50% | final price |
| Acadia Healthcare (ACHC) | the next day | +5.29% | final price |
| Acadia Healthcare (ACHC) | two days later | +3.19% | final price |
| Acadia Healthcare (ACHC) | three days later | -0.33% | final price |
| Acadia Healthcare (ACHC) | three days earlier | -5.32% | final price |
| Acadia Healthcare (ACHC) | five days earlier | -3.46% | final price |
| Ascendis Pharma A/S (ASND) | that day | -1.62% | final price |
| Ascendis Pharma A/S (ASND) | the next day | +0.04% | final price |
| Ascendis Pharma A/S (ASND) | two days later | -0.14% | final price |
| Ascendis Pharma A/S (ASND) | three days later | -0.76% | final price |
| Ascendis Pharma A/S (ASND) | three days earlier | -1.88% | final price |
| Ascendis Pharma A/S (ASND) | five days earlier | -0.35% | final price |
| aTYR PHARMA (ATYR) | that day | -7.79% | final price |
| aTYR PHARMA (ATYR) | the next day | -16.23% | final price |
| aTYR PHARMA (ATYR) | two days later | -14.52% | final price |
| aTYR PHARMA (ATYR) | three days later | -18.17% | final price |
| aTYR PHARMA (ATYR) | three days earlier | +18.40% | final price |
| aTYR PHARMA (ATYR) | five days earlier | +30.15% | final price |
| BridgeBio Pharma (BBIO) | that day | -3.73% | final price |
| BridgeBio Pharma (BBIO) | the next day | -1.23% | final price |
| BridgeBio Pharma (BBIO) | two days later | +2.10% | final price |
| BridgeBio Pharma (BBIO) | three days later | +0.97% | final price |
| BridgeBio Pharma (BBIO) | three days earlier | -1.08% | final price |
| BridgeBio Pharma (BBIO) | five days earlier | +1.84% | final price |
| Cardiff Oncology (CRDF) | that day | -2.88% | final price |
| Cardiff Oncology (CRDF) | the next day | -6.73% | final price |
| Cardiff Oncology (CRDF) | two days later | -6.73% | final price |
| Cardiff Oncology (CRDF) | three days later | -13.46% | final price |
| Cardiff Oncology (CRDF) | three days earlier | +1.92% | final price |
| Cardiff Oncology (CRDF) | five days earlier | +2.88% | final price |
Who reported a NewAmsterdam Pharma Co N.V (NAMS) trade near this story
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around NewAmsterdam Pharma Co N.V (NAMS)
Companies mentioned with this story
- NAMS NewAmsterdam Pharma Co N.V
In “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care,” NewAmsterdam Pharma Co N.V (NAMS) is linked, with no stored direction, medium confidence. Reason on file: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ACHC Acadia Healthcare
In “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care.” Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence in the 13 Oct 2026 story “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care.” Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- CRDF Cardiff Oncology
For “Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care,” Cardiff Oncology (CRDF) is linked, with no stored direction, medium confidence. Reason on file: GA selected CRDF as a RELATED security because its canonical security name directly matches this event's themes: oncology. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
NewAmsterdam Pharma Co N.V (NAMS)
“Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care” (13 Oct 2026) reaches NewAmsterdam Pharma Co N.V (NAMS) through this story.
What ties NewAmsterdam Pharma Co N.V (NAMS) to the headline is this: GA selected NAMS as a RELATED security because its canonical security name directly matches this event's themes: pharma, shares. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
A second company, Acadia Healthcare (ACHC), is listed for a different reason: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
The price range for NewAmsterdam Pharma Co N.V (NAMS), and the dates in the story
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. NAMS traded between 19.58 and 25.10 across 20 sessions. The latest close on file is 20.49.
A simple score for NewAmsterdam Pharma Co N.V (NAMS)
46 out of 100
“Liver Cancer Survivor Shares Why Patients Should Speak Up About Their Care” scores 46 out of 100. The score uses 1 sources, and 6 linked companies.